SCHEMBL1286423

SCHEMBL1286423

O=P(O)(O)OCC(O)COP(=O)(O)O

nearest known ligand 0.64

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PGK1 P00558 1/20 0.58
PGK2 P07205 1/20 0.58
LPAR5 Q9H1C0 2/20 0.57
PGD P52209 3/20 0.54
MPI P34949 1/20 0.54
LPAR1 Q92633 5/20 0.52
LPAR6 P43657 1/20 0.52
LPAR4 Q99677 1/20 0.52
LPAR2 Q9HBW0 1/20 0.52
LPAR3 Q9UBY5 1/20 0.52
ENPP2 Q13822 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24706048 0.92 PGK1 (0.52) PGK1PGK2LPAR5PGDMPI
SCHEMBL3950043 0.92 LPAR5 (0.61) PGK1PGK2LPAR5PGDMPI
SCHEMBL12282272 0.92 PGK1 (0.52) PGK1PGK2LPAR5PGDMPI
SCHEMBL12282586 0.92 PGK1 (0.52) PGK1PGK2LPAR5PGDMPI
SCHEMBL12283192 0.92 PGK1 (0.52) PGK1PGK2LPAR5PGDMPI
SCHEMBL11956581 0.88 LPAR5 (0.58) PGK1PGK2LPAR5PGDMPI
SCHEMBL28221875 0.88 LPAR5 (0.49) PGK1PGK2LPAR5PGDMPI
SCHEMBL6655023 0.87 PGK1 (0.52) PGK1PGK2LPAR5PGDMPI
SCHEMBL3340798 0.87 PGK1 (0.52) PGK1PGK2LPAR5PGDMPI
SCHEMBL213379 0.87 PGK1 (0.52) PGK1PGK2LPAR5PGDMPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120085971-A1 Process for Producing Thermally Surface Postcrosslinked Water-Absorbing Polymer Particles BASF SE (DE) 2012-04-12 US claimed
CN-112669904-B Screening method for phosphoglycerate kinase and substrate binding mode 中国科学院大连化学物理研究所 2024-03-01 CN disclosed
CN-116790462-A Universal platform strain with high-carbon-atom economical central metabolic network, and construction method and application thereof 山东大学 2023-09-22 CN disclosed
CN-113817677-B Use of pantothenic acid or derivatives thereof and alpha-D-glucose-1, 6-biphosphoric acid or derivatives thereof for promoting DC migration 四川大学 2023-08-18 CN disclosed
US-20220395516-A1 PHARMACEUTICAL COMPOSITIONS FOR CLINICAL NUTRITION BAXTER HEALTHCARE SA (CH) 2022-12-15 US disclosed
CN-114717253-A Streptococcus suis efficient transposition mutation system and application thereof 华中农业大学 2022-07-08 CN disclosed
US-20220119821-A1 RECOMBINANT HOST CELLS AND METHODS FOR THE PRODUCTION OF ASPARTIC ACID AND B-ALANINE UNITED STATES DEPARTMENT OF ENERGY 2022-04-21 US disclosed
CN-113481104-B Aspergillus flavus-resistant crop growth-promoting spore-free trichoderma preparation and application thereof 暨南大学 2022-04-01 CN disclosed
EP-3810786-A1 RECOMBINANT HOST CELLS AND METHODS FOR THE PRODUCTION OF ASPARTIC ACID AND BETA-ALANINE Lygos, Inc. (US) 2021-04-28 EP disclosed
CN-112669904-A Method for screening phosphoglycerate kinase and substrate combination mode 中国科学院大连化学物理研究所 2021-04-16 CN disclosed
US-20120191434-A1 ARTICLES OF MANUFACTURE AND METHODS FOR MODELING CHINESE HAMSTER OVARY (CHO) CELL METABOLISM GT LIFE SCIENCES, INC. (US) 2012-07-26 US disclosed
US-20120085971-A1 Process for Producing Thermally Surface Postcrosslinked Water-Absorbing Polymer Particles BASF SE (DE) 2012-04-12 US disclosed
WO-2011120707-A1 COMPOSITIONS FOR DENTAL TREATMENT COMPRISING LIPOTEICHOIC ACIDS OR PARTS THEREOF LIKE MONO- OR POLYGLYCERPHOSPHATES LUNAMED AG (CH) 2011-10-06 WO disclosed
CN-101679940-A Metabolically engineered microorganism useful for the production of 1,2-propanediol METABOLIC EXPLORER SA 2010-03-24 CN disclosed
CN-101611151-A Ruthenium purple biosensor UNIV WARWICK (GB) 2009-12-23 CN disclosed
CN-100536923-C Method for expressing human insulin for reducing blood sugar by transgenic lucid ganoderma ZHONGPING LIN (CN) 2009-09-09 CN disclosed
CN-1450083-A Citrullinylarginine dipeptide analogs and their dermatological uses as care and treatment agents EXSYMOL SA (MC) 2003-10-22 CN disclosed
US-5610180-A TOCOPHEROL AND CHOLESTEROL DERIVATIVES, CYTOPROTECTIVE AGENTS VIRGINIA COMMONWEALTH UNIVERSITY (US) 1997-03-11 US disclosed
US-5336485-A Administering cholestane phthalates, succinates or sulfates before administering tacrine CENTER FOR INNOVATIVE TECHNOLOGY (US) 1994-08-09 US disclosed
US-5198432-A Cytoprotective agents CENTER FOR INNOVATIVE TECHNOLOGY (US) 1993-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220395516-A1 PHARMACEUTICAL COMPOSITIONS FOR CLINICAL NUTRITION AGPAT2, G6PC1, AGPS PGK1 466/4885PGK2 552/4885LPAR5 457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.